On January 31st and February 1st, the Reagan-Udall Foundation for the Food and Drug Administration hosted a two-day virtual meeting, Advancing Psychedelic Clinical Study Design. The below commentary, written by Psychedelic Alpha’s Josh Hardman, is certainly not exhaustive, but rather aims to share a selection of observations from the event. It’s ordered broadly chronologically.
